Advertisement
As of 11:26AM EST. Market open.
| Previous Close | 99.18 |
| Open | 100.08 |
| Bid | 100.87 x 800 |
| Ask | 100.87 x 800 |
| Day's Range | 99.51 - 101.38 |
| 52 Week Range | 94.48 - 134.63 |
| Volume | |
| Avg. Volume | 9,900,732 |
| Market Cap | 256.29B |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | 21.20 |
| EPS (TTM) | 4.78 |
| Earnings Date | Feb 04, 2025 |
| Forward Dividend & Yield | 3.24 (3.27%) |
| Ex-Dividend Date | Dec 16, 2024 |
| 1y Target Est | 130.85 |
Business WireMerck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
RAHWAY, N.J., November 25, 2024--Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
Insider MonkeyMerck & Co., Inc. (MRK): Among the Most Promising Cancer Stocks According to Hedge Funds
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one of the leading causes of death […]
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.